Dermsquared Scheduled Maintenance, Thursday Feb 29, 6:30am to 8:30am EST

On-Demand CME Videos

What Dermatologist Need to Know about Chronic Spontaneous Urticaria and the Role of Biologics

About

This activity was recorded at the Fall Clinical Dermatology Conference 2023. 

What Dermatologist Need to Know about Chronic Spontaneous Urticaria and the Role of Biologics 

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

December 6, 2023

Expiration Date:

December 31, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Describe strategies to diagnose patients with CSU

  • Describe the role of biologics for the management of CSU

  • Identify strategies to incorporate biologics for the management of CSU into everyday dermatology practice

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Mark
Mark Lebwohl, MD

Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

George
George Lewitt, MD

Dermatologist
Illinois Dermatology Institute
Chicago, IL

Dawn
Dawn Merritt, DO

Dermatology Residency Program Director
OhioHealth Riverside Hospital
Columbus, OH

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Mark Lebwohl, MD

Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.

Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.

George M. Lewitt, MD

Advisory Board: Dermavant, Pfizer, Galderma, Janssen, Lilly, UCB Grant/Research Support: Amgen, Abbvie, Lilly, DermTech, Dermavant, Aobiome, Novan 

Consultant: Dermavant, Pfizer, Galderma, Janssen, Lilly, UCB Speakers’ Bureau or Honoraria: Abbvie, Arcutis, Lilly, Janssen, Pfizer, Dermavant, BMS, Incyte, UCB, Orthodermatologics

Dawn L. Merritt, DO

Consultant: Abbvie, Arcutis, BMS, Dermavant, Lilly, Novartis, UCB
Speaker's Bureau or Honoraria: Abbvie, Amgen, BMS, Dermavent, LEO, Lilly, Pfizer

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved